Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.

Ther Adv Respir Dis · 2020 · PMC7052452 · PMID 32106777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Revefenacin produced similar, nominally significant improvements from baseline in trough FEV 1 than placebo in the LABA and non-LABA subgroups.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.